These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25163001)

  • 41. Direct protein-protein conjugation by genetically introducing bioorthogonal functional groups into proteins.
    Kim S; Ko W; Sung BH; Kim SC; Lee HS
    Bioorg Med Chem; 2016 Nov; 24(22):5816-5822. PubMed ID: 27670101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.
    Zhao RY; Wilhelm SD; Audette C; Jones G; Leece BA; Lazar AC; Goldmacher VS; Singh R; Kovtun Y; Widdison WC; Lambert JM; Chari RV
    J Med Chem; 2011 May; 54(10):3606-23. PubMed ID: 21517041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bispecifics and antibody-drug conjugates: A positive synergy.
    Maruani A
    Drug Discov Today Technol; 2018 Dec; 30():55-61. PubMed ID: 30553521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Site-specific incorporation of unnatural amino acids into proteins by cell-free protein synthesis.
    Ozawa K; Loh CT
    Methods Mol Biol; 2014; 1118():189-203. PubMed ID: 24395417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expanding the chemistry of fluorescent protein biosensors through genetic incorporation of unnatural amino acids.
    Niu W; Guo J
    Mol Biosyst; 2013 Dec; 9(12):2961-70. PubMed ID: 24080788
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic incorporation of recycled unnatural amino acids.
    Ko W; Kim S; Jo K; Lee HS
    Amino Acids; 2016 Feb; 48(2):357-63. PubMed ID: 26358464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Template-Catalyzed, Disulfide Conjugation of Monoclonal Antibodies Using a Natural Amino Acid Tag.
    King JD; Ma Y; Kuo YC; Bzymek KP; Goodstein LH; Meyer K; Moore RE; Crow D; Colcher DM; Singh G; Horne DA; Williams JC
    Bioconjug Chem; 2018 Jun; 29(6):2074-2081. PubMed ID: 29763554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards the next generation of biomedicines by site-selective conjugation.
    Hu QY; Berti F; Adamo R
    Chem Soc Rev; 2016 Mar; 45(6):1691-719. PubMed ID: 26796469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incorporation of unnatural amino acids for synthetic biology.
    Voloshchuk N; Montclare JK
    Mol Biosyst; 2010 Jan; 6(1):65-80. PubMed ID: 20024068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor.
    Manjappa AS; Chaudhari KR; Venkataraju MP; Dantuluri P; Nanda B; Sidda C; Sawant KK; Murthy RS
    J Control Release; 2011 Feb; 150(1):2-22. PubMed ID: 21095210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis of metal-carbonyl-dendrimer-antibody immunoconjugates: towards a new format for carbonyl metallo immunoassay.
    Fischer-Durand N; Salmain M; Rudolf B; Vessières A; Zakrzewski J; Jaouen G
    Chembiochem; 2004 Apr; 5(4):519-25. PubMed ID: 15185376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Residue-specific incorporation of unnatural amino acids into proteins in vitro and in vivo.
    Singh-Blom A; Hughes RA; Ellington AD
    Methods Mol Biol; 2013; 978():93-114. PubMed ID: 23423891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of different hapten-carrier conjugation ratios and molecular orientations on antibody affinity against a peptide antigen.
    Pedersen MK; Sorensen NS; Heegaard PM; Beyer NH; Bruun L
    J Immunol Methods; 2006 Apr; 311(1-2):198-206. PubMed ID: 16574142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generation of tumor-targeted antibody-CpG conjugates.
    Li Z; Jang JK; Lechner MG; Hu P; Khawli L; Scannell CA; Epstein AL
    J Immunol Methods; 2013 Mar; 389(1-2):45-51. PubMed ID: 23279945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery.
    Casi G; Huguenin-Dezot N; Zuberbühler K; Scheuermann J; Neri D
    J Am Chem Soc; 2012 Apr; 134(13):5887-92. PubMed ID: 22394212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adding new chemistries to the genetic code.
    Liu CC; Schultz PG
    Annu Rev Biochem; 2010; 79():413-44. PubMed ID: 20307192
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Linker technologies for antibody-drug conjugates.
    Nolting B
    Methods Mol Biol; 2013; 1045():71-100. PubMed ID: 23913142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SpyLigase-Catalyzed Modification of Antibodies.
    Siegmund V; Piater B; Fischer F; Kolmar H
    Methods Mol Biol; 2019; 2012():171-192. PubMed ID: 31161509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.